Pharma's Almanac TV
PA TV
Your Name
Your Email
Manage Account
Sign Out
Sign In
Register
Follow the Journey
Companies On The Road
Arcadis DPS Group
C2 Pharma
CAI
EcoLab
Environmental Systems Corporation
Federal Equipment Company
Globyz Biopharma Services
Grifols
Integrity
Nu-Tek BioSciences
PHARMALEX
Waters Corporation
Follow the Journey
Companies On The Road
ABS
aCGT Vector
Alconox Inc.
Andelyn Biosciences
Arranta Bio
Avid Bioservices
BDD
BIOVECTRA
DPS Group
Dynamk Capital
Environmental Systems Corporation
Federal Equipment Company
Genesis AEC
Globyz Biopharma Services
Grifols Partnership
IDT Biologika
Inceptor Bio
IPS-Integrated Project Services
Kineticos Life Sciences
MilliporeSigma
Montana BioScience Alliance
Olon
Rentschler Biopharma
SanaClis
Scorpion Biological Services
Secant Group
Tapemark
VITRONIC
Follow the Journey
Companies On The Road
AES Clean Technology
Altis Biosystems
Arranta Bio
Avara Pharmaceutical Services
Avid Bioservices
BioVectra
Centaur BPS
Dynamk Capital
ECRI
Evolve Biologics
Federal Equipment Company
Globyz
Inceptor Bio
IPS-Integrated Project Services
Olon
Pii
Polpharma Biologics
PPD
RoosterBio
SanaClis
Sanofi AIS
SGD Pharma
SPI Pharma
TriRx Pharmaceutical Services
Yourway
Dashboard
Topics
Products
ADC
API - Small Molecule
Biologics
Biopharmaceuticals
Biosimilars
Cell and Gene Therapy
DNA
Drug Product
Drug Substance
Equipment
Generics
Immunotherapy
Injectables
Monoclonal Antibody
Novel Therapeutics
Oral Solid Dosage
Orphan Drugs
Parenterals
Stem Cells
Vaccine
Services
Big Data
Bioprocessing
Clinical Trials
Continuous Manufacturing
Diagnostics
Drug Delivery
Drug Development
Drug Discovery
Facility
Formulation
Innovation
Oncology
Patient Adherence
Patient Centric
Preclinical
Process Development
Quality
Regulatory
Research
Serialization
Segment
Biomanufacturing
Biotechnology
CDMO
Consulting
CRO
Engineering
Equipment
Excipients
Healthcare
Intermediates
Logistics
Manufacturing
Packaging
Supply Chain
Business
Agreement
Appointment
Business
Capacity Expansion
Collaboration
Growth
Investment
Licensing
M&A
Market Expansion
Market Intelligence
Market Prediction
New Facility
Strategic Partnership
Magazine
Archive
Reports
Nice Insight Reports
2022 Sterile
2023 Cell & Gene Therapy
2023 mAb and Recombinant Protein
2024 API
2024 OSD
2024 ADC
2024 mRNA
2024 Mammalian Cell Culture
2024 Microbial Cell Culture
2024 Plasmids
2024 Gene Therapy
2024 Cell Therapy
2024 Sterile
Community
Company A to Z
Follow the Journey
Companies On The Road
Follow The Artist
Follow the Journey
Companies On The Road
More+
Staffing
Media Kit
Gilead Sciences, Inc. (2)
38 Articles Available
2
2
Can't find what you're looking for? Try our
advanced search
.
Collaboration
TARGET PharmaSolutions® to Advance Research in NASH and Hepatitis B Through New Collaboration with Gilead Sciences
PR-M11-18-NI-089
Generics
Gilead Makes Move to Launch Early Generics
PAO-M10-18-NI-001
HIV Diagnoses
Gilead Announces New Data on the Impact of Truvada® for Pre-Exposure Prophylaxis (PrEP) on the Number of HIV Diagnoses in the United States
PR-M07-18-NI-087
Inflammatory Disease
Gilead Sciences and Verily Life Sciences LLC Enter Collaboration, Hope to Better Understand Inflammatory Diseases
PAO-M05-18-NI-002
Gilead Announces Data from New Preclinical Study Evaluating a Combination of an Investigational TLR7 Agonist and an Investigational HIV Envelope
PR-M03-18-NI-021
Appointment
Gilead Sciences Announces Senior Management Change
PR-M02-18-NI-101
Oncology
Kite, a Gilead Company, And Sangamo Therapeutics Announce Collaboration To Develop Next-Generation Engineered Cell Therapies For The Treatment Of Cancer
PR-M02-18-NI-95
CAR-T
Pfizer Joins Gilead in CAR-T Development
PAO-M01-18-NI-044
Acquisition
Gilead’s new Kite Subsidiary To Buy CAR-T Cell Therapy Company Cell Design Labs
PAO-M01-18-NI-001
Research
Gilead Makes $100 Million Commitment to Fighting HIV/AIDs
PAO-M12-17-NI-038
Drug Development
U.S. Patient Receives Kite’s Yescarta CART-T Therapy
PAO-M12-17-NI-008
Acquistion
Kite Pharma Acquisition by Gilead Finalized
PAO-M10-17-NI-017
Acquisition
Gilead Sciences to Fly Kite Pharma for $11.9 Billion
PAO-M08-17-NI-036
FDA
Vosevi Hepatitis C Treatment Approved by the FDA
PAO-M07-17-NI-028
«
2
2
.svg)
